Cellectis Says Phase 1 Lasme-cel Study Shows 100% Response Rate in B-Cell Leukemia Patients

MT Newswires Live06-11 23:57

Cellectis (CLLS) said Thursday that data from a phase 1 trial of lasme-cel in relapsed/refractory B-cell acute lymphoblastic leukemia, or r/r B-ALL, reflected strong response and remission rates.

The study included 45 patients with r/r B-ALL who had received at least three prior lines of therapy. Of these, 15 patients received the recommended phase 2 dose, and seven were in the target phase 2 population, the company said.

In the target phase 2 population, lasme-cel showed an overall response rate of 100%, with 57% achieving complete remission or complete remission with incomplete count recovery. Of these, 75% achieved minimal residual disease negativity, and all patients proceeded to hematopoietic stem cell transplantation, the company said.

The company also shared preliminary data from the NATHALI-01 study evaluating eti-cel, a therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. Results show that, in the optimal dose group, overall response rate and complete response were 88% and 63%, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2642233239?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-11 23:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642233239","market":"fut","top_or_hot":-1,"title":"Cellectis Says Phase 1 Lasme-cel Study Shows 100% Response Rate in B-Cell Leukemia Patients","media":"MT Newswires Live","content":"<html><body><p> Cellectis (CLLS) said Thursday that data from a phase 1 trial of lasme-cel in relapsed/refractory B-cell acute lymphoblastic leukemia, or r/r B-ALL, reflected strong response and remission rates.</p><p>The study included 45 patients with r/r B-ALL who had received at least three prior lines of therapy. Of these, 15 patients received the recommended phase 2 dose, and seven were in the target phase 2 population, the company said.</p><p>In the target phase 2 population, lasme-cel showed an overall response rate of 100%, with 57% achieving complete remission or complete remission with incomplete count recovery. Of these, 75% achieved minimal residual disease negativity, and all patients proceeded to hematopoietic stem cell transplantation, the company said.</p><p>The company also shared preliminary data from the NATHALI-01 study evaluating eti-cel, a therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. Results show that, in the optimal dose group, overall response rate and complete response were 88% and 63%, respectively.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cellectis Says Phase 1 Lasme-cel Study Shows 100% Response Rate in B-Cell Leukemia Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCellectis Says Phase 1 Lasme-cel Study Shows 100% Response Rate in B-Cell Leukemia Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-11 23:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Cellectis (CLLS) said Thursday that data from a phase 1 trial of lasme-cel in relapsed/refractory B-cell acute lymphoblastic leukemia, or r/r B-ALL, reflected strong response and remission rates.</p><p>The study included 45 patients with r/r B-ALL who had received at least three prior lines of therapy. Of these, 15 patients received the recommended phase 2 dose, and seven were in the target phase 2 population, the company said.</p><p>In the target phase 2 population, lasme-cel showed an overall response rate of 100%, with 57% achieving complete remission or complete remission with incomplete count recovery. Of these, 75% achieved minimal residual disease negativity, and all patients proceeded to hematopoietic stem cell transplantation, the company said.</p><p>The company also shared preliminary data from the NATHALI-01 study evaluating eti-cel, a therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. Results show that, in the optimal dose group, overall response rate and complete response were 88% and 63%, respectively.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CLLS","symbol_name":"Cellectis S.A.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2642233239","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642233239","pubTimestamp":1781193431,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cellectis (CLLS) said Thursday that data from a phase 1 trial of lasme-cel in relapsed/refractory B-cell acute lymphoblastic leukemia, or r/r B-ALL, reflected strong response and remission rates.The s","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CLLS":"Cellectis S.A.","BK4139":"生物科技"},"translate_title":"Cellectis表示1期Lasme-cel研究显示B细胞白血病患者应答率为100%","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLLS":1},"content_text":"Cellectis (CLLS) said Thursday that data from a phase 1 trial of lasme-cel in relapsed/refractory B-cell acute lymphoblastic leukemia, or r/r B-ALL, reflected strong response and remission rates.The study included 45 patients with r/r B-ALL who had received at least three prior lines of therapy. Of these, 15 patients received the recommended phase 2 dose, and seven were in the target phase 2 population, the company said.In the target phase 2 population, lasme-cel showed an overall response rate of 100%, with 57% achieving complete remission or complete remission with incomplete count recovery. Of these, 75% achieved minimal residual disease negativity, and all patients proceeded to hematopoietic stem cell transplantation, the company said.The company also shared preliminary data from the NATHALI-01 study evaluating eti-cel, a therapy for relapsed/refractory B-cell non-Hodgkin lymphoma. Results show that, in the optimal dose group, overall response rate and complete response were 88% and 63%, respectively.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642233239","isCrawlerRequest":true}